Sorafinib in kidney cancer
Author:
Open Access
- 1 July 2007
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 18 (suppl_9) , ix90-ix93
Abstract
B Escudier; Sorafinib in kidney cancer, Annals of Oncology, Volume 18, Issue suppl_9, 1 July 2007, Pages ix90–ix93, https://doi.org/10.1093/annonc/mdm301Keywords
This publication has 14 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumoursBritish Journal of Cancer, 2005
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid TumorsJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumorsInternational Journal of Cancer, 2003
- Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumorsInt. Journal of Clinical Pharmacology and Therapeutics, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine KinasesJournal of Biological Chemistry, 1997